Share this article
Share this article
ResearchAndMarkets.com s offering.
This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) provides insights across retinal diseases, viral and non-viral vector platforms for gene therapies, allogeneic cell therapy, bone repair, gluten antigen-specific drug therapy for Celiac disease, plant-based anti-cancer agents, and food colors. Further, PCR-free whole genome sequencing, oral protein-drug delivery technology for insulin, and cryo transmission electron microscope for viral protein analysis are discussed.
The Life Science, Health & Wellness TOE will feature disruptive technology advances in the global life sciences industry. The technologies and innovations profiled will encompass developments across genetic engineering, drug discovery and development, biomarkers, tissue engineering, synthetic biology, microbiome, disease management, as well as health and wellness among several other platforms.
Pharma Leader Series: Top 50 Ophthalmic Drug Manufacturers Market Report 2021-2031
In-depth Analysis of Top 50 Ophthalmic Drug Manufacturers: Capabilities, Results, Competition and Sales Potentials Visiongain has published a new Pharma Leader Series report on Top 50 Ophthalmic Drug Manufacturers Market Report 2021-2031.
May 05, 2021 10:45 ET | Source: ReportLinker ReportLinker Lyon, FRANCE
New York, May 05, 2021 (GLOBE NEWSWIRE) Reportlinker.com announces the release of the report Pharma Leader Series: Top 50 Ophthalmic Drug Manufacturers Market Report 2021-2031 - https://www.reportlinker.com/p06067745/?utm source=GNW The global ophthalmic drugs manufacturers market is estimated to be valued at US$xx billion in 2021 and is projected to reach at a market value of US$xx billion by 2031.
Vertua Limited (NSX:VERA) Cosmos Investment Impact - ABN Newswire (@ABN_Newswire) abnnewswire.net - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from abnnewswire.net Daily Mail and Mail on Sunday newspapers.
Wize Pharma set for switch to Bitcoin mining
Wize Pharma has spun off its ophthalmology drug development activities, and will begin to mine digital currencies in another month through Cosmos.
Wize Pharma (OTCQB: WIZP), from Hod Hasharon, has reported that it has met all the preconditions for implementing the offer to purchase the shares of Australian bitcoin miner Cosmos Capital Ltd. Wize Pharma expects to complete the purchase of the shares by March 9, 2021. One of the conditions was that the level of response should be a minimum of 90% of Cosmos shareholders, and as of yesterday a response had been received (including a commitment to respond) of Cosmos shareholders, holding about 94.5% of the company s equity.
Wize Pharma s Takeover Offer for Cosmos Capital Declared Unconditional
USA - English
News provided by
Share this article
Share this article
HOD HASHARON, Israel, Feb. 16, 2021 /PRNewswire/ Wize Pharma, Inc. (OTCQB: WIZP), a clinical-stage biopharmaceutical company focused on the treatment of ophthalmic disorders, today announced that it has declared its previously announced off-market takeover offer ( Offer ) for all of the ordinary shares in Cosmos Capital Limited, a leading digital infrastructure provider based in Sydney, Australia ( Cosmos ), free from all of the conditions set out in the Offer and, accordingly, the Offer has become unconditional. A formal notice of the unconditionality of the Offer, as required under section 650F of the Corporations Act 2001 (Australia), is attached as Annexure A below.